CEL-SCI Corporation (NYSEMKT:CVM) announced that Geert Kersten Chief Executive Officer will be presenting at the 2014 BIO International Convention on Wednesday June 25th at 2:00 p.m. PDT. Hosted by the Biotechnology Industry Organization (BIO) this year’s global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego California. CEL-SCI Corporation (NYSEMKT:CVM) stock performance was -6.40% in last session and finished the day at $1.17. Traded volume was 811,061.00million shares in the last session and the average volume of the stock remained 798.33K shares. The beta of the stock remained 1.58. CEL-SCI Corporation (NYSEMKT:CVM) insider ownership is 1.40%.
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, demonstrated continuing progress with its IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor program at the American Society for Clinical Oncology (ASCO) 2014 annual meeting. NewLink Genetics Corp (NASDAQ:NLNK) rose 1.76 percent to $26.58 Tuesday on volume of 594,946.00million shares. The intra-day range of the stock was $26.12 to $28.58. NewLink Genetics Corp (NASDAQ:NLNK) has a market capitalization of $740.90million.
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its earnings data on Wednesday. The company reported ($5.38) EPS for the quarter, Analyst Ratings.Net reports. The company had revenue of $4.80 million for the quarter, compared to the consensus estimate of $4.60 million. Alder Biopharmaceuticals Inc (NASDAQ:ALDR)’s stock on June 24, 2014 reported a decrease of -2.71% to the closing price of $18.32. Its fifty two weeks range is $9.50 -$22.95. The total market capitalization recorded $564.32million. The overall volume in the last trading session was 193,628.00million shares. In its share capital, ALDR has 29.91million outstanding shares.
CytRx Corporation (NASDAQ:CYTR) on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). On Tuesday, shares of CytRx Corporation (NASDAQ:CYTR) dropped -6.88% to close the day at $4.33. Company return on investment (ROI) is -257.90% and its monthly performance is recorded as 13.65%. CytRx Corporation (NASDAQ:CYTR) quarterly revenue growth is 17.34%.
StemCells Inc (NASDAQ:STEM) on June 9 announced that based on positive interim results, it has closed enrollment in its Phase I/II clinical trial for dry age-related macular degeneration (AMD) in order to focus its efforts on a follow-on Phase II randomized, controlled proof-of-concept study, later this year. StemCells Inc (NASDAQ:STEM) stock performance was -6.12% in last session and finished the day at $1.84. Traded volume was 3.84million shares in the last session and the average volume of the stock remained 1.62million shares. The beta of the stock remained 1.47. StemCells Inc (NASDAQ:STEM) insider ownership is 5.90%.